Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer

Ajjai Alva, Luke Nordquist, Stephanie Daignault, Saby George, Jorge Ramos, Costantine Albany, Sudhir Isharwal, Matthew McDonald, Gregory Campbell, Pongwut Danchaivijitr, Sarah Yentz, Aseem Anand, Evan Y. Yu

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

BACKGROUND: We sought to identify potential clinical variables associated with outcomes after radium-223 therapy in routine practice. METHODS: Consecutive non-trial mCRPC patients who received ≥1 dose of radium dichloride-223 at four academic and one community urology-specific cancer centers from May 2013 to June 2014 were retrospectively identified. Association of baseline and on-therapy clinical variables with number of radium doses received and clinical outcomes including overall survival were analyzed using chi-square statistics, cox proportional hazards, and Kaplan–Meier methods. Bone Scan Index (BSI) was derived from available bone scans using EXINI software. RESULTS: One hundred and forty-five patients were included. Radium-223 was administered for six cycles in 74 patients (51%). One-year survival in this heavily pre-treated population was 64% (95%CI: 54–73%). In univariate and multivariate analysis, survival was highly associated with receiving all six doses of Radium-223. Receipt of six doses was associated with ECOG PS of 0–1, lower baseline PSA & pain level, no prior abiraterone/enzalutamide, <5 BSI value, and normal alkaline phosphatase. In patients who reported baseline pain (n = 72), pain declined in 51% after one dose and increased in 7%. PSA declined ≥50% in 16% (18/110). Alkaline phosphatase declined ≥25% in 48% (33/69) and ≥50% in 16/69 patients. BSI declined in 17 (68%) of the 25 patients who had bone scan available at treatment follow-up. Grade ≥3 neutropenia, anemia, and thrombocytopenia occurred in 4% (n = 114), 4% (n = 125), and 5% (n = 123), respectively. CONCLUSIONS: Patients earlier in their disease course with <5 BSI, low pain score, and good ECOG performance status are optimal candidates for radium-223. Radium-223 therapy is well tolerated with most patients reporting declines in pain scores and BSI. Prostate 77:479–488, 2017.

Original languageEnglish (US)
Pages (from-to)479-488
Number of pages10
JournalProstate
Volume77
Issue number5
DOIs
StatePublished - Apr 1 2017

Fingerprint

Radium
Castration
Prostatic Neoplasms
Bone and Bones
Pain
Therapeutics
Alkaline Phosphatase
Survival
Urology
Neutropenia
Thrombocytopenia
Anemia
Prostate
Reference Values
Software
Multivariate Analysis

Keywords

  • Bone Scan Index
  • outcomes
  • variables

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Alva, A., Nordquist, L., Daignault, S., George, S., Ramos, J., Albany, C., ... Yu, E. Y. (2017). Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. Prostate, 77(5), 479-488. https://doi.org/10.1002/pros.23286

Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. / Alva, Ajjai; Nordquist, Luke; Daignault, Stephanie; George, Saby; Ramos, Jorge; Albany, Costantine; Isharwal, Sudhir; McDonald, Matthew; Campbell, Gregory; Danchaivijitr, Pongwut; Yentz, Sarah; Anand, Aseem; Yu, Evan Y.

In: Prostate, Vol. 77, No. 5, 01.04.2017, p. 479-488.

Research output: Contribution to journalArticle

Alva, A, Nordquist, L, Daignault, S, George, S, Ramos, J, Albany, C, Isharwal, S, McDonald, M, Campbell, G, Danchaivijitr, P, Yentz, S, Anand, A & Yu, EY 2017, 'Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer', Prostate, vol. 77, no. 5, pp. 479-488. https://doi.org/10.1002/pros.23286
Alva A, Nordquist L, Daignault S, George S, Ramos J, Albany C et al. Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. Prostate. 2017 Apr 1;77(5):479-488. https://doi.org/10.1002/pros.23286
Alva, Ajjai ; Nordquist, Luke ; Daignault, Stephanie ; George, Saby ; Ramos, Jorge ; Albany, Costantine ; Isharwal, Sudhir ; McDonald, Matthew ; Campbell, Gregory ; Danchaivijitr, Pongwut ; Yentz, Sarah ; Anand, Aseem ; Yu, Evan Y. / Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. In: Prostate. 2017 ; Vol. 77, No. 5. pp. 479-488.
@article{1b7e5a4d6d7d47daacb5ca506f107d0c,
title = "Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer",
abstract = "BACKGROUND: We sought to identify potential clinical variables associated with outcomes after radium-223 therapy in routine practice. METHODS: Consecutive non-trial mCRPC patients who received ≥1 dose of radium dichloride-223 at four academic and one community urology-specific cancer centers from May 2013 to June 2014 were retrospectively identified. Association of baseline and on-therapy clinical variables with number of radium doses received and clinical outcomes including overall survival were analyzed using chi-square statistics, cox proportional hazards, and Kaplan–Meier methods. Bone Scan Index (BSI) was derived from available bone scans using EXINI software. RESULTS: One hundred and forty-five patients were included. Radium-223 was administered for six cycles in 74 patients (51{\%}). One-year survival in this heavily pre-treated population was 64{\%} (95{\%}CI: 54–73{\%}). In univariate and multivariate analysis, survival was highly associated with receiving all six doses of Radium-223. Receipt of six doses was associated with ECOG PS of 0–1, lower baseline PSA & pain level, no prior abiraterone/enzalutamide, <5 BSI value, and normal alkaline phosphatase. In patients who reported baseline pain (n = 72), pain declined in 51{\%} after one dose and increased in 7{\%}. PSA declined ≥50{\%} in 16{\%} (18/110). Alkaline phosphatase declined ≥25{\%} in 48{\%} (33/69) and ≥50{\%} in 16/69 patients. BSI declined in 17 (68{\%}) of the 25 patients who had bone scan available at treatment follow-up. Grade ≥3 neutropenia, anemia, and thrombocytopenia occurred in 4{\%} (n = 114), 4{\%} (n = 125), and 5{\%} (n = 123), respectively. CONCLUSIONS: Patients earlier in their disease course with <5 BSI, low pain score, and good ECOG performance status are optimal candidates for radium-223. Radium-223 therapy is well tolerated with most patients reporting declines in pain scores and BSI. Prostate 77:479–488, 2017.",
keywords = "Bone Scan Index, outcomes, variables",
author = "Ajjai Alva and Luke Nordquist and Stephanie Daignault and Saby George and Jorge Ramos and Costantine Albany and Sudhir Isharwal and Matthew McDonald and Gregory Campbell and Pongwut Danchaivijitr and Sarah Yentz and Aseem Anand and Yu, {Evan Y.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1002/pros.23286",
language = "English (US)",
volume = "77",
pages = "479--488",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer

AU - Alva, Ajjai

AU - Nordquist, Luke

AU - Daignault, Stephanie

AU - George, Saby

AU - Ramos, Jorge

AU - Albany, Costantine

AU - Isharwal, Sudhir

AU - McDonald, Matthew

AU - Campbell, Gregory

AU - Danchaivijitr, Pongwut

AU - Yentz, Sarah

AU - Anand, Aseem

AU - Yu, Evan Y.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - BACKGROUND: We sought to identify potential clinical variables associated with outcomes after radium-223 therapy in routine practice. METHODS: Consecutive non-trial mCRPC patients who received ≥1 dose of radium dichloride-223 at four academic and one community urology-specific cancer centers from May 2013 to June 2014 were retrospectively identified. Association of baseline and on-therapy clinical variables with number of radium doses received and clinical outcomes including overall survival were analyzed using chi-square statistics, cox proportional hazards, and Kaplan–Meier methods. Bone Scan Index (BSI) was derived from available bone scans using EXINI software. RESULTS: One hundred and forty-five patients were included. Radium-223 was administered for six cycles in 74 patients (51%). One-year survival in this heavily pre-treated population was 64% (95%CI: 54–73%). In univariate and multivariate analysis, survival was highly associated with receiving all six doses of Radium-223. Receipt of six doses was associated with ECOG PS of 0–1, lower baseline PSA & pain level, no prior abiraterone/enzalutamide, <5 BSI value, and normal alkaline phosphatase. In patients who reported baseline pain (n = 72), pain declined in 51% after one dose and increased in 7%. PSA declined ≥50% in 16% (18/110). Alkaline phosphatase declined ≥25% in 48% (33/69) and ≥50% in 16/69 patients. BSI declined in 17 (68%) of the 25 patients who had bone scan available at treatment follow-up. Grade ≥3 neutropenia, anemia, and thrombocytopenia occurred in 4% (n = 114), 4% (n = 125), and 5% (n = 123), respectively. CONCLUSIONS: Patients earlier in their disease course with <5 BSI, low pain score, and good ECOG performance status are optimal candidates for radium-223. Radium-223 therapy is well tolerated with most patients reporting declines in pain scores and BSI. Prostate 77:479–488, 2017.

AB - BACKGROUND: We sought to identify potential clinical variables associated with outcomes after radium-223 therapy in routine practice. METHODS: Consecutive non-trial mCRPC patients who received ≥1 dose of radium dichloride-223 at four academic and one community urology-specific cancer centers from May 2013 to June 2014 were retrospectively identified. Association of baseline and on-therapy clinical variables with number of radium doses received and clinical outcomes including overall survival were analyzed using chi-square statistics, cox proportional hazards, and Kaplan–Meier methods. Bone Scan Index (BSI) was derived from available bone scans using EXINI software. RESULTS: One hundred and forty-five patients were included. Radium-223 was administered for six cycles in 74 patients (51%). One-year survival in this heavily pre-treated population was 64% (95%CI: 54–73%). In univariate and multivariate analysis, survival was highly associated with receiving all six doses of Radium-223. Receipt of six doses was associated with ECOG PS of 0–1, lower baseline PSA & pain level, no prior abiraterone/enzalutamide, <5 BSI value, and normal alkaline phosphatase. In patients who reported baseline pain (n = 72), pain declined in 51% after one dose and increased in 7%. PSA declined ≥50% in 16% (18/110). Alkaline phosphatase declined ≥25% in 48% (33/69) and ≥50% in 16/69 patients. BSI declined in 17 (68%) of the 25 patients who had bone scan available at treatment follow-up. Grade ≥3 neutropenia, anemia, and thrombocytopenia occurred in 4% (n = 114), 4% (n = 125), and 5% (n = 123), respectively. CONCLUSIONS: Patients earlier in their disease course with <5 BSI, low pain score, and good ECOG performance status are optimal candidates for radium-223. Radium-223 therapy is well tolerated with most patients reporting declines in pain scores and BSI. Prostate 77:479–488, 2017.

KW - Bone Scan Index

KW - outcomes

KW - variables

UR - http://www.scopus.com/inward/record.url?scp=85006980987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006980987&partnerID=8YFLogxK

U2 - 10.1002/pros.23286

DO - 10.1002/pros.23286

M3 - Article

VL - 77

SP - 479

EP - 488

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 5

ER -